

Japan's NEC and Biomy to expand Al-based analytical platforms in digital pathology

10 January 2025 | News

To deliver the promises of precision medicine to cancer patients



Japan-based NEC Corporation and Biomy, Inc. have signed a Memorandum of Understanding (MoU) for a joint marketing partnership to develop and expand artificial intelligence/deep learning (AI/DL)-based analytical platforms in the field of digital pathology. Through this partnership, the two companies aim to promote precision medicine for cancer patients and contribute to the advancement of the healthcare industry.

This partnership integrates the cutting-edge AI technologies developed by NEC and Biomy with the primary objectives to enhance the DeepPathFinder platform for discovering new pathological biomarkers through AI/DL-based digital pathology image analysis, leverage data derived from pathological images, and support precision medicine and treatment planning, particularly in the field of cancer care.

The resulting AI/DL-driven pathological biomarker discovery tool will then be offered to pharmaceutical/biotech companies and academia through the provision of the following:

- 1. An automated digital pathology platform for independently exploring pathological biomarkers from pathology images.
- 2. Full-fledged digital pathological biomarker discovery services offered through partnerships with NEC and Biomy.
- 3. Guidance and support for obtaining regulatory approval for medical devices utilising the newly discovered pathological biomarkers.